Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	MAP kinase kinase kinase activity	MAP3K3 TAOK2 MAP3K9 MAP3K2	1.60e-05	27	114	4	GO:0004709
GeneOntologyMolecularFunction	peptide lactyltransferase (CoA-dependent) activity	CREBBP EP300	3.23e-05	2	114	2	GO:0120300
GeneOntologyMolecularFunction	histone H3K27 acetyltransferase activity	CREBBP EP300	3.23e-05	2	114	2	GO:0044017
GeneOntologyMolecularFunction	protein serine kinase activity	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	4.44e-05	363	114	10	GO:0106310
GeneOntologyMolecularFunction	histone H3K18 acetyltransferase activity	CREBBP EP300	9.66e-05	3	114	2	GO:0043993
GeneOntologyMolecularFunction	protein serine/threonine kinase activity	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	2.40e-04	446	114	10	GO:0004674
GeneOntologyMolecularFunction	cytoskeletal motor activity	KIF27 CENPE DYNC2H1 MYO5C MYO16	5.82e-04	118	114	5	GO:0003774
GeneOntologyBiologicalProcess	intracellular transport	MON2 CCDC91 MKKS CLTCL1 IPO8 DYNC2H1 VPS39 SYNE1 AHCTF1 BARD1 RANBP6 MYO5C CAPN10 NUP205 EVI5 ATP6V0D1 PPP6C NF2 ABCE1 RAB3GAP2 TRAPPC10 IFT122 ATP6V0D2 MAP2K2 EP300 HTT	1.05e-07	1496	113	26	GO:0046907
GeneOntologyBiologicalProcess	protein localization to organelle	CDK9 SLF1 IPO8 KALRN DYNC2H1 SYNE1 UBL4B APC BARD1 RANBP6 CUBN CREBBP FSIP2 NF2 RAB3GAP2 IFT122 EP300 GOLGB1 HTT	7.05e-06	1091	113	19	GO:0033365
GeneOntologyBiologicalProcess	organelle assembly	MKKS KIF27 CENPE DYNC2H1 SYNE1 PRC1 EVI5 FSIP2 ATP6V0D1 NF2 ERAL1 RAB3GAP2 IFT122 DNAAF1 EP300 CCDC136 DEUP1 HTT	4.54e-05	1138	113	18	GO:0070925
GeneOntologyCellularComponent	plasma membrane proton-transporting V-type ATPase complex	ATP6V0D1 ATP6V0D2	3.00e-05	2	115	2	GO:0033181
GeneOntologyCellularComponent	microtubule organizing center	MKKS FBXL13 SLF1 CDKL2 LRRC49 CCDC18 APC EVI5 ATP6V0D1 PDE4DIP NINL NLRC5 IFT122 DEUP1 HTT	1.56e-04	919	115	15	GO:0005815
HumanPheno	Pilomatrixoma	APC CREBBP EP300	2.22e-05	9	34	3	HP:0030434
HumanPheno	Plantar crease between first and second toes	CREBBP EP300	4.32e-05	2	34	2	HP:0008107
HumanPheno	Aortic isthmus hypoplasia	CREBBP EP300	4.32e-05	2	34	2	HP:0034227
HumanPheno	High axial triradius	CREBBP EP300	4.32e-05	2	34	2	HP:0001042
HumanPheno	Neoplasm of the oral cavity	DYNC2H1 APC CASP10 NF2 PLCB4	4.81e-05	62	34	5	HP:0100649
HumanPheno	Keloids	APC CREBBP EP300	7.43e-05	13	34	3	HP:0010562
HumanPheno	Laryngeal cartilage malformation	CREBBP EP300	1.29e-04	3	34	2	HP:0008752
HumanPheno	Phobia	CREBBP EP300	1.29e-04	3	34	2	HP:5200232
HumanPheno	Agoraphobia	CREBBP EP300	1.29e-04	3	34	2	HP:0000756
HumanPheno	Humoral immunodeficiency	CREBBP EP300	1.29e-04	3	34	2	HP:0005363
HumanPheno	Prominent nasal septum	CREBBP EP300	1.29e-04	3	34	2	HP:0005322
HumanPheno	Radial deviation of thumb terminal phalanx	CREBBP EP300	1.29e-04	3	34	2	HP:0005895
HumanPheno	Neoplasm of the tongue	DYNC2H1 CASP10 NF2 PLCB4	1.55e-04	42	34	4	HP:0100648
HumanPheno	Skin appendage neoplasm	APC CREBBP EP300	2.07e-04	18	34	3	HP:0012842
HumanPheno	Talipes	MKKS CLTCL1 IPO8 CENPE DYNC2H1 SYNE1 CREBBP SNX14 RAB3GAP2 CHD6 EP300 HTT	2.29e-04	583	34	12	HP:0001883
HumanPheno	Positional foot deformity	MKKS CLTCL1 IPO8 CENPE DYNC2H1 SYNE1 CREBBP SNX14 RAB3GAP2 CHD6 EP300 HTT	2.44e-04	587	34	12	HP:0005656
HumanPheno	Trichiasis	CREBBP EP300	2.57e-04	4	34	2	HP:0001128
HumanPheno	Visceral hemangioma	CREBBP EP300	2.57e-04	4	34	2	HP:0410266
HumanPheno	Talon cusp	CREBBP EP300	2.57e-04	4	34	2	HP:0011087
HumanPheno	Widened distal phalanges	CREBBP EP300	2.57e-04	4	34	2	HP:0006200
HumanPheno	Vascular ring	CREBBP EP300	2.57e-04	4	34	2	HP:0010775
HumanPheno	Hepatic hemangioma	CREBBP EP300	2.57e-04	4	34	2	HP:0031207
HumanPheno	Hydronephrosis	MKKS IPO8 DYNC2H1 APC CREBBP RAB3GAP2 MAP2K2 EP300	2.61e-04	264	34	8	HP:0000126
HumanPheno	Absent earlobe	CENPE CREBBP EP300	2.87e-04	20	34	3	HP:0000387
HumanPheno	Dental crowding	MKKS TRIO CREBBP SNX14 PLCB4 EP300	3.22e-04	144	34	6	HP:0000678
HumanPheno	Self-mutilation	CLTCL1 TRIO CREBBP EP300	3.31e-04	51	34	4	HP:0000742
HumanPheno	Convex nasal ridge	CENPE APC CREBBP CHD6 EP300	3.68e-04	95	34	5	HP:0000444
HumanPheno	Full cheeks	CREBBP SNX14 PLCB4 IFT122 MAP2K2 EP300	4.16e-04	151	34	6	HP:0000293
HumanPheno	Papillary cystadenoma of the epididymis	CREBBP EP300	4.27e-04	5	34	2	HP:0009715
HumanPheno	Supernumerary cusp	CREBBP EP300	4.27e-04	5	34	2	HP:0033777
HumanPheno	Epididymal neoplasm	CREBBP EP300	4.27e-04	5	34	2	HP:0030421
HumanPheno	High, narrow palate	IPO8 APC CREBBP CHD6 IFT122 EP300	4.95e-04	156	34	6	HP:0002705
HumanPheno	Dilatation of the renal pelvis	MKKS IPO8 DYNC2H1 APC CREBBP RAB3GAP2 MAP2K2 EP300	4.95e-04	290	34	8	HP:0010946
HumanPheno	Aplasia/Hypoplasia involving bones of the feet	CENPE DYNC2H1 APC RAB3GAP2 CHD6 IFT122 EP300 HTT	5.95e-04	298	34	8	HP:0006494
HumanPheno	Abnormal renal pelvis morphology	MKKS IPO8 DYNC2H1 APC CREBBP RAB3GAP2 MAP2K2 EP300	6.22e-04	300	34	8	HP:0010944
HumanPheno	Large foramen magnum	CREBBP EP300	6.38e-04	6	34	2	HP:0002700
HumanPheno	Delayed ability to walk	DOCK3 TRIO SYNE1 CUBN CREBBP RAB3GAP2 TRAPPC10 EP300	6.79e-04	304	34	8	HP:0031936
HumanPheno	Broad distal phalanx of finger	CREBBP IFT122 EP300	7.12e-04	27	34	3	HP:0009836
HumanPheno	Abnormal sternum morphology	IPO8 TRIO DYNC2H1 SYNE1 CREBBP SNX14 RAB3GAP2 IFT122 MAP2K2 EP300	7.44e-04	474	34	10	HP:0000766
Domain	ARM-like	MON2 ZYG11A SETX IPO8 APC RANBP6 RIPOR3 PSME4 UNC45B HTT PPP6R3	8.12e-07	270	114	11	IPR011989
Domain	ARM-type_fold	MON2 DOCK3 ZYG11A CLTCL1 IPO8 APC RANBP6 PPP6R1 PSME4 UNC45B HTT PPP6R3	1.11e-06	339	114	12	IPR016024
Domain	-	MON2 ZYG11A IPO8 APC RANBP6 RIPOR3 PSME4 UNC45B HTT	8.86e-06	222	114	9	1.25.10.10
Domain	Nuc_rcpt_coact_CREBbp	CREBBP EP300	3.69e-05	2	114	2	IPR014744
Domain	ZnF_TAZ	CREBBP EP300	3.69e-05	2	114	2	SM00551
Domain	-	CREBBP EP300	3.69e-05	2	114	2	1.20.1020.10
Domain	RING_CBP-p300	CREBBP EP300	3.69e-05	2	114	2	IPR010303
Domain	-	CREBBP EP300	3.69e-05	2	114	2	1.10.1630.10
Domain	Creb_binding	CREBBP EP300	3.69e-05	2	114	2	PF09030
Domain	vATP-synt_AC39	ATP6V0D1 ATP6V0D2	3.69e-05	2	114	2	PF01992
Domain	zf-TAZ	CREBBP EP300	3.69e-05	2	114	2	PF02135
Domain	ZF_TAZ	CREBBP EP300	3.69e-05	2	114	2	PS50134
Domain	KAT11	CREBBP EP300	3.69e-05	2	114	2	SM01250
Domain	Znf_TAZ	CREBBP EP300	3.69e-05	2	114	2	IPR000197
Domain	KIX	CREBBP EP300	3.69e-05	2	114	2	PF02172
Domain	ATPase_V0-cplx_dsu	ATP6V0D1 ATP6V0D2	3.69e-05	2	114	2	IPR016727
Domain	HAT_KAT11	CREBBP EP300	3.69e-05	2	114	2	PF08214
Domain	KIX	CREBBP EP300	3.69e-05	2	114	2	PS50952
Domain	CBP_P300_HAT	CREBBP EP300	3.69e-05	2	114	2	IPR031162
Domain	ATPase_V0-cplx_csu/dsu	ATP6V0D1 ATP6V0D2	3.69e-05	2	114	2	IPR002843
Domain	DUF902	CREBBP EP300	3.69e-05	2	114	2	PF06001
Domain	-	CREBBP EP300	3.69e-05	2	114	2	1.10.246.20
Domain	Histone_AcTrfase_Rtt109/CBP	CREBBP EP300	3.69e-05	2	114	2	IPR013178
Domain	KIX_dom	CREBBP EP300	3.69e-05	2	114	2	IPR003101
Domain	CBP_P300_HAT	CREBBP EP300	3.69e-05	2	114	2	PS51727
Domain	Ser/Thr_kinase_AS	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	6.71e-05	357	114	10	IPR008271
Domain	S_TKc	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	7.03e-05	359	114	10	SM00220
Domain	PROTEIN_KINASE_ST	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	7.53e-05	362	114	10	PS00108
Domain	SAPS	PPP6R1 PPP6R3	1.10e-04	3	114	2	IPR007587
Domain	SAPS	PPP6R1 PPP6R3	1.10e-04	3	114	2	PF04499
Domain	Pkinase	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	1.15e-04	381	114	10	PF00069
Domain	ZF_ZZ_2	DTNB CREBBP EP300	1.69e-04	18	114	3	PS50135
Domain	ZF_ZZ_1	DTNB CREBBP EP300	1.69e-04	18	114	3	PS01357
Domain	ZZ	DTNB CREBBP EP300	1.69e-04	18	114	3	PF00569
Domain	Znf_ZZ	DTNB CREBBP EP300	2.00e-04	19	114	3	IPR000433
Domain	ZnF_ZZ	DTNB CREBBP EP300	2.00e-04	19	114	3	SM00291
Domain	TIR	TLR10 TLR3 IL1RL1	2.72e-04	21	114	3	SM00255
Domain	TIR	TLR10 TLR3 IL1RL1	3.13e-04	22	114	3	PF01582
Domain	Spectrin	TRIO KALRN SYNE1	3.59e-04	23	114	3	PF00435
Domain	-	TLR10 TLR3 IL1RL1	3.59e-04	23	114	3	3.40.50.10140
Domain	LRR_1	FBXL13 LRRC49 LRRIQ4 TLR10 TLR3 NLRC5 DNAAF1	3.94e-04	219	114	7	PF00560
Domain	TIR	TLR10 TLR3 IL1RL1	4.08e-04	24	114	3	PS50104
Domain	TIR_dom	TLR10 TLR3 IL1RL1	4.62e-04	25	114	3	IPR000157
Domain	PROTEIN_KINASE_ATP	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	5.08e-04	459	114	10	PS00107
Domain	FERM_C	EPB41L5 NF2 FRMD6	5.20e-04	26	114	3	PF09380
Domain	Nuc_rcpt_coact	CREBBP EP300	5.45e-04	6	114	2	IPR009110
Domain	FERM_PH-like_C	EPB41L5 NF2 FRMD6	5.82e-04	27	114	3	IPR018980
Domain	FERM_C	EPB41L5 NF2 FRMD6	5.82e-04	27	114	3	SM01196
Domain	-	TRIO KALRN EPB41L5 TBC1D4 NF2 FRMD6 OSBPL7 PLCB4 RASAL2	6.60e-04	391	114	9	2.30.29.30
Domain	Spectrin_repeat	TRIO KALRN SYNE1	7.21e-04	29	114	3	IPR002017
Domain	CHCR	CLTCL1 VPS39	7.60e-04	7	114	2	PS50236
Domain	-	ZYG11A FBXL13 LRRC49 LRRIQ4 TLR10 TLR3 NLRC5 DNAAF1	7.93e-04	321	114	8	3.80.10.10
Domain	Prot_kinase_dom	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	8.27e-04	489	114	10	IPR000719
Domain	PROTEIN_KINASE_DOM	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	8.80e-04	493	114	10	PS50011
Domain	L_dom-like	ZYG11A FBXL13 LRRC49 LRRIQ4 TLR10 TLR3 NLRC5 DNAAF1	9.12e-04	328	114	8	IPR032675
Domain	SPEC	TRIO KALRN SYNE1	9.66e-04	32	114	3	SM00150
Domain	Spectrin/alpha-actinin	TRIO KALRN SYNE1	9.66e-04	32	114	3	IPR018159
Domain	Clathrin_H-chain/VPS_repeat	CLTCL1 VPS39	1.01e-03	8	114	2	IPR000547
Domain	FERM_N	EPB41L5 NF2 FRMD6	1.06e-03	33	114	3	IPR018979
Domain	FERM_N	EPB41L5 NF2 FRMD6	1.06e-03	33	114	3	PF09379
Domain	PH_dom-like	TRIO KALRN EPB41L5 TBC1D4 NF2 FRMD6 OSBPL7 PLCB4 RASAL2	1.21e-03	426	114	9	IPR011993
Domain	Leu-rich_rpt	FBXL13 LRRC49 LRRIQ4 TLR10 TLR3 NLRC5 DNAAF1	1.38e-03	271	114	7	IPR001611
Domain	LRR	LRRC49 LRRIQ4 TLR10 TLR3 NLRC5 DNAAF1	1.47e-03	201	114	6	PS51450
Domain	Leu-rich_rpt_4	LRRIQ4 NLRC5	1.61e-03	10	114	2	IPR025875
Domain	LRR_4	LRRIQ4 NLRC5	1.61e-03	10	114	2	PF12799
Domain	Kinase-like_dom	CDK9 TRIO KALRN CDKL2 MAP3K3 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	1.79e-03	542	114	10	IPR011009
Domain	Protein_kinase_ATP_BS	CDK9 KALRN CDKL2 TAOK2 MAP3K9 MAP2K2 MAP3K2 DYRK2	2.27e-03	379	114	8	IPR017441
Domain	FERM_M	EPB41L5 NF2 FRMD6	2.78e-03	46	114	3	PF00373
Domain	TPR-like_helical_dom	CLTCL1 IFIT2 NAA25 UNC45B TRAPPC10 IFT122	3.08e-03	233	114	6	IPR011990
Domain	PB1	MAP3K3 MAP3K2	3.20e-03	14	114	2	SM00666
Domain	PB1	MAP3K3 MAP3K2	3.20e-03	14	114	2	PF00564
Domain	PB1	MAP3K3 MAP3K2	3.20e-03	14	114	2	PS51745
Domain	PB1_dom	MAP3K3 MAP3K2	3.20e-03	14	114	2	IPR000270
Domain	-	EPB41L5 NF2 FRMD6	3.33e-03	49	114	3	1.20.80.10
Domain	FERM_central	EPB41L5 NF2 FRMD6	3.33e-03	49	114	3	IPR019748
Domain	FERM_domain	EPB41L5 NF2 FRMD6	3.33e-03	49	114	3	IPR000299
Domain	FERM/acyl-CoA-bd_prot_3-hlx	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	IPR014352
Domain	FERM_1	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	PS00660
Domain	FERM_2	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	PS00661
Domain	FERM_3	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	PS50057
Domain	Band_41_domain	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	IPR019749
Domain	B41	EPB41L5 NF2 FRMD6	3.52e-03	50	114	3	SM00295
Domain	AT_hook	AHCTF1 DOT1L	4.19e-03	16	114	2	PF02178
Domain	LRR_6	FBXL13 TLR3 NLRC5	4.61e-03	55	114	3	PF13516
Domain	P-loop_NTPase	SETX KIF27 CENPE DYNC2H1 SLFN14 MYO5C ABCE1 ERAL1 NLRC5 CHD6 MYO16 CARD14	5.62e-03	848	114	12	IPR027417
Domain	Leu-rich_rpt_Cys-con_subtyp	FBXL13 NLRC5	5.90e-03	19	114	2	IPR006553
Domain	LRR_CC	FBXL13 NLRC5	5.90e-03	19	114	2	SM00367
Pathway	KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY	CREBBP TLR3 EP300	1.73e-05	9	85	3	M47451
Pathway	BIOCARTA_PITX2_PATHWAY	APC CREBBP EP300	9.14e-05	15	85	3	MM1439
Pathway	BIOCARTA_PITX2_PATHWAY	APC CREBBP EP300	1.12e-04	16	85	3	M8516
Pathway	BIOCARTA_TGFB_PATHWAY	APC CREBBP EP300	1.35e-04	17	85	3	MM1509
Pathway	BIOCARTA_TGFB_PATHWAY	APC CREBBP EP300	1.91e-04	19	85	3	M18933
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY	MCU PLCB4 HTT	3.43e-04	23	85	3	M47676
Pathway	BIOCARTA_PELP1_PATHWAY	CREBBP EP300	3.55e-04	5	85	2	MM1575
Pathway	REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES	CREBBP EP300	3.55e-04	5	85	2	M48020
Pathway	REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES	CREBBP EP300	3.55e-04	5	85	2	M48023
Pathway	REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION	CREBBP EP300	3.55e-04	5	85	2	M27228
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CDK9 SETX TRIO SPATA18 CCDC18 APC EPB41L5 MAP3K3 FSIP2 ESYT2 TBC1D4 FRMD6 RAB3GAP2 MAP3K9 MAP2K2 GOLGB1 RASAL2 MAP3K2 DYRK2	8.82e-11	861	117	19	36931259
Pubmed	Charting the landscape of tandem BRCT domain-mediated protein interactions.	CCDC91 CDK9 ELOA DYNC2H1 SPATA18 BARD1 PPP6R1 CUBN CREBBP GTF3C5 ESYT2 ATP6V0D1 PPP6C ERAL1 RAB3GAP2 MAP2K2 PPP6R3	1.14e-10	670	117	17	22990118
Pubmed	An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.	MON2 ELOA IPO8 DYNC2H1 CCDC150 CREBBP GTF3C5 MAP3K3 NUP205 TBC1D4 GTF3C2 SND1 MCU NINL TRAPPC10 IFT122 PACRG DNAAF1 RASAL2 MAP3K2 DYRK2	3.07e-09	1321	117	21	27173435
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	TRIO DTNB BARD1 CREBBP TFAP4 TASOR2 PKNOX2 ESYT2 TBC1D4 NF2 CDK5RAP1 NLRC5 TRMT13 CHD6 PLCB4 IFT122 ELK3 PACRG MAP2K2 EP300 GOLGB1 HTT	4.66e-09	1489	117	22	28611215
Pubmed	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.	CDK9 TRIO DTNB CREBBP MAP3K3 PPP6C SND1 ABCE1 PDE4DIP MAP3K9 ANKRD36 MAP2K2 EP300 MAP3K2 PPP6R3 DYRK2	7.25e-08	910	117	16	36736316
Pubmed	Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.	IPO8 DYNC2H1 SYNE1 AHCTF1 CCDC18 NAP1L4 EPB41L5 PPP6R1 ESYT2 GTF3C2 PPP6C NF2 SND1 ERAL1 RAB3GAP2 CDK5RAP1 IFT122 GOLGB1 RASAL2 PPP6R3	1.19e-07	1487	117	20	33957083
Pubmed	Human protein phosphatase PP6 regulatory subunits provide Sit4-dependent and rapamycin-sensitive sap function in Saccharomyces cerevisiae.	PPP6R1 PPP6C PPP6R3	1.48e-07	4	117	3	19621075
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MON2 CDK9 DOCK3 CLTCL1 TRIO KALRN VPS39 PPP6R1 TAOK2 PSME4 NF2 SND1 NINL NLRC5 DOT1L EP300 HTT	1.83e-07	1105	117	17	35748872
Pubmed	Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.	APC PPP6R1 TBC1D4 PPP6C NF2 NINL TRAPPC10 MAP2K2 RASAL2 MAP3K2 PPP6R3	3.50e-07	446	117	11	24255178
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	AHCTF1 NAP1L4 CREBBP GTF3C5 GTF3C2 NF2 SND1 RAB3GAP2 DOT1L EP300 HTT PPP6R3	3.62e-07	549	117	12	38280479
Pubmed	Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling.	CDKL2 CREBBP TLR3	3.69e-07	5	117	3	15502848
Pubmed	Different functional modes of p300 in activation of RNA polymerase III transcription from chromatin templates.	GTF3C5 GTF3C2 EP300	3.69e-07	5	117	3	18644873
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	TRIO APC NAP1L4 PPP6R1 ESYT2 TBC1D4 RASAL2 PPP6R3	5.79e-07	209	117	8	36779422
Pubmed	Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX.	PPP6R1 PPP6C PPP6R3	7.37e-07	6	117	3	20065038
Pubmed	A conserved acetylation switch enables pharmacological control of tubby-like protein stability.	CDK9 GTF3C2 RAB3GAP2 PDE4DIP IFT122 EP300 SENP7 PPP6R3	9.43e-07	223	117	8	33187986
Pubmed	CLEC16A interacts with retromer and TRIM27, and its loss impairs endosomal trafficking and neurodevelopment.	MON2 MKKS IPO8 DYNC2H1 NAP1L4 RANBP6 PPP6R1 ESYT2 ERAL1 MCU CDK5RAP1 PPP6R3	1.02e-06	606	117	12	36538041
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	SETX KIF27 PARP2 PPP6R1 PRC1 CREBBP TFAP4 GTF3C5 NUP205 ESYT2 TBC1D4 GTF3C2 ERAL1 EP300	1.21e-06	857	117	14	25609649
Pubmed	Protein phosphatase 6 subunit with conserved Sit4-associated protein domain targets IkappaBepsilon.	PPP6R1 PPP6C PPP6R3	2.05e-06	8	117	3	16769727
Pubmed	Protein phosphatase 6 regulatory subunits composed of ankyrin repeat domains.	PPP6R1 PPP6C PPP6R3	2.05e-06	8	117	3	18186651
Pubmed	Protein phosphatase 6 regulates mitotic spindle formation by controlling the T-loop phosphorylation state of Aurora A bound to its activator TPX2.	PPP6R1 PPP6C PPP6R3	3.07e-06	9	117	3	21187329
Pubmed	HIV-1 chromatin, transcription, and the regulatory protein Tat.	CDK9 CREBBP EP300	3.07e-06	9	117	3	24158816
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	SETX VPS39 AHCTF1 APC CUBN MAP3K3 PSME4 PPP6C NF2 ABCE1 ERAL1 MAP3K9 TRAPPC10 DOT1L GOLGB1	3.76e-06	1084	117	15	11544199
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	MON2 SETX CENPE DYNC2H1 APC PPP6R1 CREBBP TBC1D4 DOT1L GOLGB1 PPP6R3	5.06e-06	588	117	11	38580884
Pubmed	A human MAP kinase interactome.	SETX SYNE1 APC CREBBP MAP3K3 CHD6 MAP2K2 EP300 GOLGB1 MAP3K2	6.09e-06	486	117	10	20936779
Pubmed	Probing nuclear pore complex architecture with proximity-dependent biotinylation.	SYNE1 AHCTF1 APC NUP205 GOLGB1	6.44e-06	77	117	5	24927568
Pubmed	Rab40c regulates focal adhesions and PP6 activity by controlling ANKRD28 ubiquitylation.	PPP6R1 PPP6C PPP6R3	7.98e-06	12	117	3	35512830
Pubmed	HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis.	CDK9 IPO8 DYNC2H1 VPS39 SYNE1 CASP10 CREBBP NUP205 ERAL1 CHD6 EP300 GOLGB1	9.49e-06	754	117	12	35906200
Pubmed	Loss of p300 accelerates MDS-associated leukemogenesis.	CREBBP EP300	1.12e-05	2	117	2	27881875
Pubmed	The kinases MEKK2 and MEKK3 regulate transforming growth factor-β-mediated helper T cell differentiation.	MAP3K3 MAP3K2	1.12e-05	2	117	2	21333552
Pubmed	The COOH-terminal domain of huntingtin interacts with RhoGEF kalirin and modulates cell survival.	KALRN HTT	1.12e-05	2	117	2	29789657
Pubmed	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.	CREBBP EP300	1.12e-05	2	117	2	34845315
Pubmed	p300 plays a critical role in maintaining cardiac mitochondrial function and cell survival in postnatal hearts.	CREBBP EP300	1.12e-05	2	117	2	19729597
Pubmed	Expression, purification and characterization of human vacuolar-type H(+)-ATPase subunit d1 and d2 in Escherichia coli.	ATP6V0D1 ATP6V0D2	1.12e-05	2	117	2	24631925
Pubmed	CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.	CREBBP EP300	1.12e-05	2	117	2	39287984
Pubmed	Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH.	CREBBP EP300	1.12e-05	2	117	2	20717166
Pubmed	Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase.	MAP3K3 MAP3K2	1.12e-05	2	117	2	8621389
Pubmed	Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.	CREBBP HTT	1.12e-05	2	117	2	16456924
Pubmed	The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.	CREBBP EP300	1.12e-05	2	117	2	25893291
Pubmed	Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.	CREBBP EP300	1.12e-05	2	117	2	11559821
Pubmed	CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.	CREBBP EP300	1.12e-05	2	117	2	32576962
Pubmed	Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.	CREBBP EP300	1.12e-05	2	117	2	19822209
Pubmed	A specific CBP/p300-dependent gene expression programme drives the metabolic remodelling in late stages of spermatogenesis.	CREBBP EP300	1.12e-05	2	117	2	24522976
Pubmed	CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement.	CREBBP EP300	1.12e-05	2	117	2	21847097
Pubmed	Huntingtin-associated protein 1 (HAP1) binds to a Trio-like polypeptide, with a rac1 guanine nucleotide exchange factor domain.	KALRN HTT	1.12e-05	2	117	2	9285789
Pubmed	p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes.	CREBBP EP300	1.12e-05	2	117	2	34813504
Pubmed	Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.	CREBBP HTT	1.12e-05	2	117	2	15994095
Pubmed	Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.	CREBBP HTT	1.12e-05	2	117	2	16766198
Pubmed	Rubinstein-Taybi Syndrome	CREBBP EP300	1.12e-05	2	117	2	20301699
Pubmed	Potential biomarker of metformin action.	CREBBP EP300	1.12e-05	2	117	2	24639469
Pubmed	The histone acetyl transferases CBP and p300 regulate stress response pathways in synovial fibroblasts at transcriptional and functional levels.	CREBBP EP300	1.12e-05	2	117	2	37816914
Pubmed	Binding of p300/CBP co-activators by polyoma large T antigen.	CREBBP EP300	1.12e-05	2	117	2	11438528
Pubmed	Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators.	CREBBP EP300	1.12e-05	2	117	2	10918613
Pubmed	Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.	CREBBP EP300	1.12e-05	2	117	2	35502657
Pubmed	p300 and cAMP response element-binding protein-binding protein in skeletal muscle homeostasis, contractile function, and survival.	CREBBP EP300	1.12e-05	2	117	2	31898871
Pubmed	Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.	CREBBP EP300	1.12e-05	2	117	2	30888860
Pubmed	Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.	CREBBP EP300	1.12e-05	2	117	2	27881443
Pubmed	Recognition of Double-Stranded RNA and Regulation of Interferon Pathway by Toll-Like Receptor 10.	TLR10 TLR3	1.12e-05	2	117	2	29616030
Pubmed	Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts.	CREBBP EP300	1.12e-05	2	117	2	19272189
Pubmed	Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.	CREBBP EP300	1.12e-05	2	117	2	32690000
Pubmed	CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice.	CREBBP EP300	1.12e-05	2	117	2	30953353
Pubmed	Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.	CREBBP EP300	1.12e-05	2	117	2	21803292
Pubmed	HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.	CREBBP EP300	1.12e-05	2	117	2	9811832
Pubmed	Mitotic motor CENP-E cooperates with PRC1 in temporal control of central spindle assembly.	CENPE PRC1	1.12e-05	2	117	2	31174204
Pubmed	Two independent regions of simian virus 40 T antigen increase CBP/p300 levels, alter patterns of cellular histone acetylation, and immortalize primary cells.	CREBBP EP300	1.12e-05	2	117	2	24089570
Pubmed	Early alteration of epigenetic-related transcription in Huntington's disease mouse models.	CREBBP HTT	1.12e-05	2	117	2	29967375
Pubmed	Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP.	TRIO KALRN	1.12e-05	2	117	2	26858404
Pubmed	Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.	CREBBP EP300	1.12e-05	2	117	2	15706485
Pubmed	AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.	CREBBP EP300	1.12e-05	2	117	2	39266679
Pubmed	A boy with classical Rubinstein-Taybi syndrome but no detectable mutation in the CREBBP and EP300 genes.	CREBBP EP300	1.12e-05	2	117	2	22303793
Pubmed	Mieap suppresses murine intestinal tumor via its mitochondrial quality control.	SPATA18 APC	1.12e-05	2	117	2	26216032
Pubmed	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.	CREBBP EP300	1.12e-05	2	117	2	34732714
Pubmed	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.	CREBBP EP300	1.12e-05	2	117	2	34019788
Pubmed	Endogenous CCAAT/enhancer binding protein beta and p300 are both regulated by growth hormone to mediate transcriptional activation.	CREBBP EP300	1.12e-05	2	117	2	15860545
Pubmed	Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.	CREBBP EP300	1.12e-05	2	117	2	29460469
Pubmed	Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.	CREBBP EP300	1.12e-05	2	117	2	24551300
Pubmed	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.	CREBBP EP300	1.12e-05	2	117	2	33911074
Pubmed	The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co-activator family, including the CREB-binding protein CBP and p300.	CREBBP EP300	1.12e-05	2	117	2	9018065
Pubmed	Coactivators p300 and CBP maintain the identity of mouse embryonic stem cells by mediating long-range chromatin structure.	CREBBP EP300	1.12e-05	2	117	2	24648406
Pubmed	CBP and P300 regulate distinct gene networks required for human primary myoblast differentiation and muscle integrity.	CREBBP EP300	1.12e-05	2	117	2	30135524
Pubmed	Distribution of co-activators CBP and p300 during mouse oocyte and embryo development.	CREBBP EP300	1.12e-05	2	117	2	16596650
Pubmed	The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.	CREBBP EP300	1.12e-05	2	117	2	29217654
Pubmed	Differences in the interactions of oncogenic adenovirus 12 early region 1A and nononcogenic adenovirus 2 early region 1A with the cellular coactivators p300 and CBP.	CREBBP EP300	1.12e-05	2	117	2	10049825
Pubmed	CBP/p300 acetyltransferase activity in hematologic malignancies.	CREBBP EP300	1.12e-05	2	117	2	27380996
Pubmed	CREBBP and p300 lysine acetyl transferases in the DNA damage response.	CREBBP EP300	1.12e-05	2	117	2	29170789
Pubmed	Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.	CREBBP EP300	1.12e-05	2	117	2	21555743
Pubmed	Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.	CREBBP HTT	1.12e-05	2	117	2	11264541
Pubmed	CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.	CREBBP EP300	1.12e-05	2	117	2	12646247
Pubmed	Histone acetyltransferase activities of cAMP-regulated enhancer-binding protein and p300 in tissues of fetal, young, and old mice.	CREBBP EP300	1.12e-05	2	117	2	11867645
Pubmed	Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue.	CREBBP EP300	1.12e-05	2	117	2	11963968
Pubmed	Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300.	CREBBP EP300	1.12e-05	2	117	2	9528808
Pubmed	Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.	CREBBP EP300	1.12e-05	2	117	2	12696060
Pubmed	CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain.	CREBBP EP300	1.12e-05	2	117	2	36109165
Pubmed	Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.	CREBBP EP300	1.12e-05	2	117	2	12242694
Pubmed	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.	CREBBP EP300	1.12e-05	2	117	2	31182547
Pubmed	Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.	CREBBP EP300	1.12e-05	2	117	2	30635043
Pubmed	Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.	CREBBP EP300	1.12e-05	2	117	2	27648933
Pubmed	Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.	CREBBP HTT	1.12e-05	2	117	2	22116937
Pubmed	Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis.	CREBBP EP300	1.12e-05	2	117	2	10610021
Pubmed	Emerging roles of p300/CBP in autophagy and autophagy-related human disorders.	CREBBP EP300	1.12e-05	2	117	2	37314181
Pubmed	Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal.	CREBBP EP300	1.12e-05	2	117	2	12397173
Interaction	NDEL1 interactions	KALRN DTNB SYNE1 CCDC18 APC PRC1 EVI5 NINL DYRK2	4.55e-07	164	116	9	int:NDEL1
Interaction	HMGN2 interactions	MON2 SYNE1 PARP2 BARD1 LRRIQ4 PRC1 MYO5C TBC1D4 CHD6 EP300	6.33e-07	222	116	10	int:HMGN2
Interaction	YWHAH interactions	CDK9 SETX TRIO SPATA18 CCDC18 APC EPB41L5 CREBBP MAP3K3 ESYT2 TBC1D4 FRMD6 ABCE1 RAB3GAP2 MAP3K9 NINL TRAPPC10 MAP2K2 RASAL2 HTT MAP3K2	1.15e-06	1102	116	21	int:YWHAH
Interaction	PLK1 interactions	SPATA18 APC PPP6R1 PRC1 GTF3C5 EVI5 GTF3C2 PPP6C CHFR NINL CARD14 SENP7 MAP3K2 PPP6R3	1.41e-06	510	116	14	int:PLK1
Interaction	FLOT1 interactions	TRIO DTNB LRRC49 APC EPB41L5 PRC1 CAPN10 ESYT2 NF2 ABCE1 DOT1L RASAL2 HTT	3.56e-06	475	116	13	int:FLOT1
Interaction	CEP128 interactions	IPO8 DTNB LRRC49 SPATA18 CCDC18 APC NUP205 NINL RASAL2 DEUP1	8.56e-06	297	116	10	int:CEP128
Interaction	KRT8 interactions	CDK9 IPO8 AHCTF1 LRRC49 CCDC18 APC PPP6R1 NUP205 ESYT2 TBC1D4 PPP6C NINL	9.15e-06	441	116	12	int:KRT8
Interaction	GSK3B interactions	TRIO LRRC49 APC NAP1L4 PPP6R1 PRC1 NUP205 ESYT2 TBC1D4 SND1 ABCE1 TLR3 CHD6 RASAL2 MAP3K2 PPP6R3 DYRK2	9.61e-06	868	116	17	int:GSK3B
Interaction	GOLGA2 interactions	MON2 IPO8 LRRC49 UBL4B SPATA18 APC CCDC150 BARD1 NAP1L4 TFAP4 ANKRD36 DOT1L EP300 GOLGB1 DEUP1	2.03e-05	733	116	15	int:GOLGA2
Interaction	YWHAG interactions	CDK9 SPATA18 CCDC18 APC EPB41L5 PRC1 MAP3K3 TAOK2 ESYT2 TBC1D4 FRMD6 OSBPL7 MAP3K9 NINL TRAPPC10 MAP2K2 RASAL2 HTT MAP3K2 PPP6R3	2.77e-05	1248	116	20	int:YWHAG
Interaction	SMARCB1 interactions	CDK9 APC BARD1 CREBBP TFAP4 TASOR2 ATP6V0D1 CHFR DOT1L EP300	4.88e-05	364	116	10	int:SMARCB1
Interaction	ING5 interactions	CDK9 APC BARD1 EP300 DEUP1 HTT	5.14e-05	114	116	6	int:ING5
Interaction	SPECC1L interactions	ELOA KALRN APC EPB41L5 PRC1 MYO5C DOT1L	5.17e-05	167	116	7	int:SPECC1L
Interaction	YWHAB interactions	CENPE SPATA18 CCDC18 APC EPB41L5 MAP3K3 ESYT2 TBC1D4 FRMD6 MAP3K9 NINL TRAPPC10 DOT1L MAP2K2 RASAL2 HTT MAP3K2	6.88e-05	1014	116	17	int:YWHAB
Interaction	YWHAE interactions	ELOA IPO8 CENPE SPATA18 CCDC18 APC PRC1 MAP3K3 TAOK2 TBC1D4 PPP6C FRMD6 PAFAH2 MAP3K9 DOT1L MAP2K2 RASAL2 HTT MAP3K2	9.75e-05	1256	116	19	int:YWHAE
Interaction	RBM25 interactions	CDK9 VPS39 BARD1 EPB41L5 PRC1 RAB3GAP2 DOT1L EP300 HTT	1.06e-04	323	116	9	int:RBM25
Interaction	RHOF interactions	AHCTF1 EPB41L5 NUP205 ESYT2 NAA25 NF2 ABCE1 MCU PLCB4 MAP2K2 GOLGB1 RASAL2 HTT	1.34e-04	673	116	13	int:RHOF
Interaction	DIRAS3 interactions	IPO8 LRRC49 APC NAP1L4 EPB41L5 ESYT2 MAP3K9 RASAL2	1.39e-04	262	116	8	int:DIRAS3
Interaction	MYL12B interactions	CDK9 PRC1 PPP6C SND1 NINL SENP7	1.48e-04	138	116	6	int:MYL12B
Interaction	DBN1 interactions	CDK9 CLTCL1 CDKL2 NAP1L4 EPB41L5 PRC1 MYO5C NF2 DOT1L HTT	1.50e-04	417	116	10	int:DBN1
Interaction	ASH2L interactions	BARD1 EPB41L5 RAB3GAP2 DOT1L EP300 HTT PPP6R3 DYRK2	1.50e-04	265	116	8	int:ASH2L
Interaction	KRT18 interactions	CDK9 AHCTF1 LRRC49 CCDC18 APC MYO5C NUP205 PDE4DIP DOT1L EP300	1.56e-04	419	116	10	int:KRT18
Interaction	WWTR1 interactions	AHCTF1 CREBBP MAP3K3 GTF3C2 NF2 SND1 EP300 HTT MAP3K2 PPP6R3	1.65e-04	422	116	10	int:WWTR1
GeneFamily	Mitogen-activated protein kinase kinase kinases\|RAF family	MAP3K3 TAOK2 MAP3K9 MAP3K2	3.19e-06	24	78	4	654
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	DTNB CREBBP EP300	6.02e-05	18	78	3	91
GeneFamily	Protein phosphatase 6 regulatory subunits	PPP6R1 PPP6R3	2.73e-04	6	78	2	699
GeneFamily	CD molecules\|Toll like receptors	TLR10 TLR3	8.09e-04	10	78	2	948
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	EPB41L5 NF2 FRMD6	1.31e-03	50	78	3	1293
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	CREBBP EP300	2.40e-03	17	78	2	486
GeneFamily	Ankyrin repeat domain containing	SLF1 BARD1 ANKRD36 ANKFN1 MYO16	3.94e-03	242	78	5	403
GeneFamily	V-type ATPases	ATP6V0D1 ATP6V0D2	4.38e-03	23	78	2	415
GeneFamily	General transcription factors\|Xeroderma pigmentosum complementation groups\|DNA helicases\|ERCC excision repair associated	GTF3C5 GTF3C2	5.17e-03	25	78	2	565
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	TRIO KALRN IL1RL1 UNC5D	5.18e-03	161	78	4	593
GeneFamily	Cyclin dependent kinases	CDK9 CDKL2	5.58e-03	26	78	2	496
GeneFamily	Nucleoporins	AHCTF1 NUP205	8.38e-03	32	78	2	1051
Coexpression	MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_22	CLTCL1 NF2 EP300	1.39e-05	11	117	3	M11594
Coexpression	PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP	SLF1 AHCTF1 CCDC18 CCDC150 BARD1 GINS1 MYO5C	2.82e-05	195	117	7	M13736
Coexpression	GSE39820_CTRL_VS_TGFBETA1_IL6_IL23A_CD4_TCELL_UP	SLF1 CENPE AHCTF1 IFIT2 TASOR2 ESYT2 TRMT13	3.21e-05	199	117	7	M5607
Coexpression	GSE14308_TH2_VS_NAIVE_CD4_TCELL_DN	DYNC2H1 APC NAP1L4 MAP3K3 PHAF1 PPP6C MAP3K2	3.31e-05	200	117	7	M3365
ToppCell	Hippocampus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	APC RANBP6 CHD6 PLCB4 UNC5D CCDC136 MYO16	2.35e-07	161	117	7	b81b346309f3facbfbebd91cae4c5b33c7bd24ef
ToppCell	IPF-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	FBXL13 DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1 ANKFN1	7.98e-07	193	117	7	ad58f5080e0ba65c845056ea6b79037b636e9c64
ToppCell	LPS_only-Epithelial_airway-airway_epithelial-Ciliated\|LPS_only / Treatment groups by lineage, cell group, cell type	FBXL13 KIF27 SPATA18 IFT122 PACRG DNAAF1 ANKFN1	9.47e-07	198	117	7	6d90b541fde357fbb40f8f7d4e8628a48b679718
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	SETX SLF1 TRIO CASP10 TAOK2 PLCB4 ELK3	1.01e-06	200	117	7	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	KALRN DTNB PARP2 IFIT2 TLR10 ATP6V0D2	5.89e-06	170	117	6	09bcbc7eb3b1d35cf03f01ce2f2fe37373382dd4
ToppCell	E18.5-Immune-Immune_Myeloid-Megakaryocyte/Platelet\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FBXL13 KALRN SYNE1 CCDC150 RIPOR3 SLFN14	8.17e-06	180	117	6	ca2a35bfb67347e47f511589a3d0f763e6664634
ToppCell	E18.5-Immune-Immune_Myeloid-Megakaryocyte/Platelet-Megakaryocyte/Platelet-Megakaryocyte/Platelet_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FBXL13 KALRN SYNE1 CCDC150 RIPOR3 SLFN14	8.17e-06	180	117	6	4e9e8cde2919610c4ac0025b1c9819808048bc1d
ToppCell	E18.5-Immune-Immune_Myeloid-Megakaryocyte/Platelet-Megakaryocyte/Platelet\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	FBXL13 KALRN SYNE1 CCDC150 RIPOR3 SLFN14	8.17e-06	180	117	6	466381bf93c3da6a2a241daadb68e9aad2964eae
ToppCell	NS-moderate-d_16-33-Epithelial-Ciliated\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DYNC2H1 LRRC49 SPATA18 PACRG DNAAF1 ANKFN1	9.55e-06	185	117	6	5e689c2fb36ce3ac2adc8d15f67107f21cf68868
ToppCell	Control-T_cells-Cycling_NK/T_cells\|Control / group, cell type (main and fine annotations)	CENPE CCDC18 CCDC150 BARD1 PRC1 GINS1	9.55e-06	185	117	6	9766216b41ee62bbac4caa25cb98ec5627a24075
ToppCell	droplet-Spleen-nan-18m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIF27 CENPE CCDC18 BARD1 PRC1 IL1RL1	1.01e-05	187	117	6	c81d11d9fdc22dc39222f62c2888025c2e8c3e65
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	MON2 AHCTF1 TASOR2 ANKRD36 GOLGB1 MAP3K2	1.05e-05	188	117	6	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MYO5C MAP3K9 GPC5 DOT1L MYO16 RASAL2	1.05e-05	188	117	6	43a3a59f92ad93509d4166bd025aed0b1b39a008
ToppCell	PCW_10-12-Epithelial-Epithelial_proliferating-epi_proliferating2_(13)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	DOCK3 CENPE CCDC150 PRC1 MYO5C MAP3K9	1.14e-05	191	117	6	39220f4a345e328f7fa4fd462a0abeea821b3e02
ToppCell	E18.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal-Deuterosomal_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 CCDC18 DNAAF1 DEUP1	1.14e-05	191	117	6	e8d56e9f43943e9cc4dce83f2c234f19c2dd487d
ToppCell	E18.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 CCDC18 DNAAF1 DEUP1	1.14e-05	191	117	6	52e8d7dfaf1ebb6df8bf3a1f4546af59faa67657
ToppCell	PCW_07-8.5-Epithelial-Epithelial_proliferating-epi_proliferating2_(13)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	DOCK3 CENPE CDKL2 CCDC150 MYO5C MAP3K9	1.18e-05	192	117	6	25378b5e4b0cea8415ff125783511fc25a56fc00
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	KANSL1L EPB41L5 CUBN MCU NINL PACRG	1.25e-05	194	117	6	7002937e8903e037332a215d00fbc7c7843b33f2
ToppCell	IPF-Multiplet-Multiplet\|IPF / Disease state, Lineage and Cell class	DYNC2H1 SYNE1 PLCB4 PACRG DNAAF1 ANKFN1	1.29e-05	195	117	6	fce0c29574bb7aab181b9c00feb42681e285d1f2
ToppCell	IPF-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PLCB4 PACRG DNAAF1 ANKFN1	1.29e-05	195	117	6	21dbdc803c6947024dc2416e9e21c2ef0af9bc31
ToppCell	COVID-19-T_cells-Cycling_NK/T_cells\|COVID-19 / group, cell type (main and fine annotations)	CENPE CCDC18 CCDC150 BARD1 PRC1 GINS1	1.29e-05	195	117	6	764ed100c28d9bc93ee5ecabc5291c8f184d78da
ToppCell	IPF-Multiplet\|IPF / Disease state, Lineage and Cell class	DYNC2H1 SYNE1 PLCB4 PACRG DNAAF1 ANKFN1	1.29e-05	195	117	6	eacc0449ae6f3ad8002268cd061467684c6fb9a7
ToppCell	PSB-critical-LOC-Epithelial-Ciliated\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DYNC2H1 SYNE1 LRRC49 SPATA18 PACRG DNAAF1	1.36e-05	197	117	6	6865f4831eb23794fb88a8649d48d497bbae3f44
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	SLF1 KALRN SYNE1 ANKRD36 UNC5D RASAL2	1.49e-05	200	117	6	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Gen_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	SETX SLF1 CASP10 TAOK2 PLCB4 ELK3	1.49e-05	200	117	6	a2b9d1cd291d17abddc3ee2e242121412c864b8b
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	SETX SLF1 CASP10 TAOK2 PLCB4 ELK3	1.49e-05	200	117	6	b2d4e6f3e8e4da62e6b02758ab2ed8f505269f9a
ToppCell	LPS-antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	4.48e-05	148	117	5	d61123f0c811287843d066b932b4a9ff09c07c5b
ToppCell	LPS-antiTNF-Epithelial_airway-Ciliated_cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	4.48e-05	148	117	5	c8e93b87212f55774223caa385859c566fa1981f
ToppCell	metastatic_Brain-Fibroblasts-Smooth_muscle_cells\|Fibroblasts / Location, Cell class and cell subclass	FBXL13 KIF27 UBL4B TFAP4 NAA25	5.42e-05	154	117	5	423f58fc7dcef068458cbf7b4ee989e37227041e
ToppCell	Control-Epithelial_airway-Ciliated_cells-Ciliated\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	5.42e-05	154	117	5	4e3bc24043144143842627cacf6f90dda2228910
ToppCell	Control-Epithelial_airway-Ciliated_cells\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	5.42e-05	154	117	5	7556a4b2b062da5ae7ec2bbb66e745e7662db628
ToppCell	saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	DTNB TBC1D4 ABCE1 OSBPL7 TRMT13	5.42e-05	154	117	5	ec920cae12ea1d14b6c973f6e903f895f80e3c50
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	5.59e-05	155	117	5	5f1e2195a6b831e1b636f5cc3a282ca423721822
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	5.59e-05	155	117	5	0944429459f642a1bcc56edc1ec28aaecde3e2dc
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Epithelial\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRIO DYNC2H1 SYNE1 NLRC5 ATP6V0D2	6.12e-05	158	117	5	12661763d1c309106801cb710c04cd2b62d16cba
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Epithelial-epithelial_cell_of_thymus\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRIO DYNC2H1 SYNE1 NLRC5 ATP6V0D2	6.12e-05	158	117	5	e7db50d6dfaf7280a73a0d5b5aa4f43ea2762d72
ToppCell	facs-Thymus-Thymus_Flowthrough-18m-Epithelial-TECs\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRIO DYNC2H1 SYNE1 NLRC5 ATP6V0D2	6.12e-05	158	117	5	0792c39e6fc0745095af7812de2d50949540d60f
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MYO5C PHAF1 UNC45B ERAL1 PDE4DIP	6.30e-05	159	117	5	1472536eea61d4f13033efe42f128bae1614fa74
ToppCell	facs-Marrow-KLS-24m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ENPP3 SLFN14 EVI5 ANKRD36 IL1RL1	6.89e-05	162	117	5	860ebf2390b4ad86475ad54717cbefcf61cd3b2a
ToppCell	facs-Marrow-KLS-24m-Hematologic-megakaryocyte-erythroid_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ENPP3 SLFN14 EVI5 ANKRD36 IL1RL1	6.89e-05	162	117	5	14e9f8aaba308619eb9da90796c336e76cedac1f
ToppCell	PND03-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_mature\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CENPE BARD1 SLFN14 ELK3 DYRK2	7.09e-05	163	117	5	7864e966c228282b4b63c43164dba3faba21026d
ToppCell	LPS-IL1RA+antiTNF-Epithelial_airway\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SPATA18 PACRG DNAAF1 ANKFN1 DEUP1	7.30e-05	164	117	5	e4d4c59aebe5cacd4ecdb907facd044dc82a831d
ToppCell	droplet-Lung-18m-Hematologic-myeloid-Basophil/Mast_cell-basophil_l26\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DTNB SLFN14 TBC1D4 PAFAH2 IL1RL1	8.18e-05	168	117	5	0e99ecd94ab8e5372e30433d7d0aa76b4d54257a
ToppCell	droplet-Lung-18m-Hematologic-myeloid-Basophil/Mast_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DTNB SLFN14 TBC1D4 PAFAH2 IL1RL1	8.18e-05	168	117	5	34722e14f28313f2e4644b3c1861ef12958cee9f
ToppCell	droplet-Lung-nan-18m-Myeloid-Basophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DTNB SLFN14 TBC1D4 PAFAH2 IL1RL1	8.41e-05	169	117	5	f2e20049a17eee533d49bd5f24a51962d123d132
ToppCell	droplet-Lung-nan-18m-Myeloid-basophil\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DTNB SLFN14 TBC1D4 PAFAH2 IL1RL1	8.41e-05	169	117	5	4c6892551e9dec94fc62b3beab1e6d424639a1e9
ToppCell	Control-Epithelial_cells-ECM-high_epithelial\|Control / group, cell type (main and fine annotations)	EPB41L5 MYO5C GPC5 MYO16 RASAL2	8.65e-05	170	117	5	e2023d66e70983c87dacbd6181d3426488d1fc57
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_B-B-B_G2M\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CENPE DTNB CCDC18 PRC1 SAPCD1	8.65e-05	170	117	5	e08a6c5ac34c456da8c7318f104e06fca585be1f
ToppCell	367C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CCDC18 CCDC150 PRC1 GINS1 IL1RL1	8.89e-05	171	117	5	e3cab55f39879e2bd3e8bda91802181075839bc4
ToppCell	367C-Epithelial_cells-Epithelial-J_(AT1-AT2_progenitors)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	CCDC18 CCDC150 PRC1 GINS1 IL1RL1	8.89e-05	171	117	5	52fdc2a4ec36fb91583b1215362548ceb6740ae1
ToppCell	MS-CD8-proli_CD4\|MS / Condition, Cell_class and T cell subcluster	TFAP4 TASOR2 GTF3C2 TRAPPC10 DNAAF1	9.13e-05	172	117	5	0b6dd257110b3f17fa71ab18a165b091a9d5ae9a
ToppCell	FLU-Healthy-3\|FLU / Virus stimulation, Condition and Cluster	CCDC150 TAOK2 MCU PACRG CCDC136	9.39e-05	173	117	5	32b8e5b400885dbeba57a7cb2c18d882664dc285
ToppCell	FLU-Healthy-3\|Healthy / Virus stimulation, Condition and Cluster	CCDC150 TAOK2 MCU PACRG CCDC136	9.39e-05	173	117	5	26e89ac86922f1cd0100cf4d1cce37e74dd31c88
ToppCell	droplet-Lung-LUNG-1m-Lymphocytic-Proliferating_NK\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	USP49 CENPE DTNB BARD1 MCU	9.39e-05	173	117	5	31784679190fbd95fc23d7c66008eb21b8c7cc5d
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_3\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	MYO5C PHAF1 UNC45B ERAL1 PDE4DIP	9.39e-05	173	117	5	7e2149205e119cec4f5099c83c85d1e13470137a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE CCDC18 BARD1 PRC1 GINS1	9.64e-05	174	117	5	84da9faff088d05233183b425385beb054c92d1b
ToppCell	5'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC-Mature_venous_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CENPE CCDC18 PRC1 MAP3K3 ELK3	1.07e-04	178	117	5	ea10117026021c959ffc871fc377cdb3e161d264
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FBXL13 DYNC2H1 SPATA18 DNAAF1 ANKFN1	1.13e-04	180	117	5	92fb01b91261b3103454924cde56add337b41844
ToppCell	356C-Lymphocytic-CD4_T-cell-Treg_cell_1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	KIF27 PARP2 EPB41L5 TBC1D4 TRMT13	1.13e-04	180	117	5	a682a5d55c612709c9ee9fa4289d6f8bef7fe1af
ToppCell	droplet-Liver-nan-3m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SETX KALRN UNC45B ELK3 RASAL2	1.16e-04	181	117	5	fcc94f04dae98b817ec06b282d2e887804d37ae5
ToppCell	Hippocampus-Neuronal-Inhibitory\|Hippocampus / BrainAtlas - Mouse McCarroll V32	APC CHD6 UNC5D CCDC136 MYO16	1.19e-04	182	117	5	b54ae650c04dfd0759c5f5e752b9bf684dd36516
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Endothelial-blood_vessel_EC-Mature_venous_EC\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CENPE CASP10 TBC1D4 ELK3 RASAL2	1.22e-04	183	117	5	52af3c943116073c8ddd207b664342960b88929b
ToppCell	Adult-Epithelial-ciliated_cell-D175\|Adult / Lineage, Cell type, age group and donor	FBXL13 SPATA18 PACRG DNAAF1 ANKFN1	1.29e-04	185	117	5	30f4980dee6cd5959655f8d74049f3bfb5312611
ToppCell	facs-Lung-EPCAM-3m-Epithelial-Ciliated_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIF27 SPATA18 PACRG DNAAF1 ANKFN1	1.35e-04	187	117	5	04dba2ed09ee4180830bdf0191921696697ea234
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK3 MYO5C ESYT2 MCU GPC5	1.35e-04	187	117	5	87b3d0478693d4c54ff06b74e5903036b9c1ee6a
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK3 MYO5C ESYT2 MCU GPC5	1.35e-04	187	117	5	42a1267bfc27b4460b8409ada580a87c4385841c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK3 MYO5C ESYT2 MCU GPC5	1.35e-04	187	117	5	64afdea159f5e67a1e5cea35ce898aae6e80aea5
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Activated_Alv_Cap\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SLF1 CASP10 IFIT2 NLRC5 ELK3	1.35e-04	187	117	5	f3397dbc23b6c2f24e2c1ba887d8f9aef3ee01a1
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	CENPE CCDC18 CCDC150 BARD1 GINS1	1.35e-04	187	117	5	9351fa87b69a951af85b10bf91fe9b1cce8c0517
ToppCell	facs-Lung-EPCAM-3m-Epithelial-ciliated_columnar_cell_of_tracheobronchial_tree\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIF27 SPATA18 PACRG DNAAF1 ANKFN1	1.35e-04	187	117	5	805dafe22f835ece4dd091d8030d0a63b52a48dd
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRIO CDKL2 SYNE1 TBC1D4 UNC5D	1.39e-04	188	117	5	63a4b25a0a6e05f80f1a6dd91b817f3cf49e6b68
ToppCell	COPD-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.42e-04	189	117	5	3e77883db34722b9ce0a03ea74caefc92dc7feff
ToppCell	Nasal_Brush-Epithelial-Ciliated_2\|Nasal_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1	1.46e-04	190	117	5	9ce7df056bfb24d70db4c3c4a2c57d89115de877
ToppCell	Nasal_Brush-Epithelial-Ciliated_2\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1	1.46e-04	190	117	5	833481ace2800354712e2ce709d5cdfd0aed3d42
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	DOCK3 TRIO CDKL2 TBC1D4 UNC5D	1.49e-04	191	117	5	d0e9afe7b6334dd515d3e68892efdc76347a55e5
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 DNAAF1 DEUP1	1.49e-04	191	117	5	1e21de183a9c09cfb6aad3f9b948087fb6bad061
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal-Deuterosomal_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 DNAAF1 DEUP1	1.49e-04	191	117	5	8688708c9183ebcb200596501dc30cc12073f151
ToppCell	nucseq-Epithelial-Epithelial_Airway\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.49e-04	191	117	5	1c528f72c9ef3ef3a850b05e4a9715190832270c
ToppCell	E16.5-Epithelial-Epithelial_Airway\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 DNAAF1 DEUP1	1.53e-04	192	117	5	bb7eb51bc079acacde42d8e55ba06d03eba2ea28
ToppCell	343B-Lymphocytic-ILC-ILC-1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	NUP205 RAB3GAP2 IFT122 MAP2K2 HTT	1.53e-04	192	117	5	445985fe1bcd33e4f0a1704b27988fbfc9334538
ToppCell	E16.5-Epithelial-Epithelial_Airway-Ciliated/Deuterosomal-Deuterosomal\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	KIF27 CDKL2 SPATA18 DNAAF1 DEUP1	1.53e-04	192	117	5	a50a6279371b3be682e334082637b7ab76b9a6e5
ToppCell	IPF-Epithelial-Ciliated\|World / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.53e-04	192	117	5	d903bbd6c18e29e2c4cdedeb3fea1fd5ad7baa11
ToppCell	IPF-Epithelial-Ciliated\|IPF / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.53e-04	192	117	5	354adc1354bf596fbc60dd45c0169688e6f45165
ToppCell	Control-Epithelial-Ciliated\|Epithelial / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.57e-04	193	117	5	0e37d454f3735edd936ee9a5f5f516ac3aad400e
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	MON2 NAP1L4 CHD6 GOLGB1 PPP6R3	1.57e-04	193	117	5	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	moderate-Epithelial-FOXN4+\|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	DYNC2H1 MYO5C IFT122 ANKRD36 DEUP1	1.60e-04	194	117	5	5dffa578149104dda33774361e9e77b227b5f1ce
ToppCell	nucseq-Epithelial-Epithelial_Alveolar\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SYNE1 EPB41L5 MYO5C MCU GPC5	1.60e-04	194	117	5	53f3e49e91b1096f3226010e2de767efb490dfe4
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1	1.60e-04	194	117	5	b4ce60c06568123008b1081d644733cb91c28f51
ToppCell	NS-critical-d_07-13-Epithelial-Ciliated\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	DYNC2H1 LRRC49 SPATA18 PACRG ANKFN1	1.60e-04	194	117	5	1ae8a10e508e672e6677f0e3c986ac30d05adeb3
ToppCell	Control-Epithelial-Ciliated\|World / Disease state, Lineage and Cell class	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.60e-04	194	117	5	958e648138676d46698090b4046cb484083ae449
ToppCell	Bronchial_Brush-Epithelial-Ciliated_1\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1	1.60e-04	194	117	5	7a7ddccfe72a4a0dc4d1a5c809988f0069f9f1a3
ToppCell	BL-critical-LOC-Epithelial-unknown_epithelial\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	ENPP3 LRRC49 SPATA18 EVI5 PACRG	1.60e-04	194	117	5	6140ff8e776429c9593607da418b2d9c4f399d41
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_ciliated\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.64e-04	195	117	5	2d19148df56e99f66b596af2d7f9d0f10f9a9087
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DYNC2H1 LRRC49 SPATA18 PACRG DNAAF1	1.64e-04	195	117	5	0fbba312e9ba9b70b4b814b67b6eb1f6544aaf6d
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.64e-04	195	117	5	43f0c257e4bb5c627afbdfc695c1199c672842d3
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.64e-04	195	117	5	cd6cfe3ef150a4a4575e04fc8a8213cdceefa1c4
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_cycling\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	CENPE CCDC18 CCDC150 PRC1 GINS1	1.64e-04	195	117	5	926eb3fc5d028be936885bea0654a77db3107234
ToppCell	nucseq-Epithelial\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SYNE1 EPB41L5 MYO5C MCU GPC5	1.64e-04	195	117	5	9406866f99555198a9be311fbd65751b70f35446
ToppCell	moderate-Epithelial-Ciliated\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	DYNC2H1 SYNE1 SPATA18 PACRG DNAAF1	1.64e-04	195	117	5	3486eae5fdb062a75a907b896c9d7b396d2aa195
ToppCell	5'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	DYNC2H1 SPATA18 PACRG DNAAF1 ANKFN1	1.64e-04	195	117	5	e22ca35bea06aa95ff2cc771632969f5e7229ffc
Drug	Gabapentin [60142-96-3]; Up 200; 23.4uM; PC3; HT_HG-U133A	KANSL1L KALRN APC CREBBP NF2 PAFAH2 NINL IFT122 DNAAF1	8.72e-07	198	117	9	5875_UP
Drug	Roxithromycin [80214-83-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A	KANSL1L APC TFAP4 EVI5 PSME4 NF2 PAFAH2 DNAAF1	6.37e-06	190	117	8	3331_DN
Drug	Budesonide [51333-22-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	ELOA DYNC2H1 VPS39 EPB41L5 NF2 TRMT13 DNAAF1 MAP3K2	6.37e-06	190	117	8	2866_DN
Drug	Fluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; PC3; HT_HG-U133A	DTNB APC CASP10 CAPN10 TAOK2 PAFAH2 OSBPL7 SENP7	7.71e-06	195	117	8	6691_UP
Drug	(+/-)-thalidomide; Up 200; 100uM; MCF7; HG-U133A	CDK9 VPS39 BARD1 GTF3C5 CAPN10 SND1 IFT122 ELK3	8.62e-06	198	117	8	266_UP
Drug	Sisomicin sulfate [53179-09-2]; Down 200; 2.8uM; PC3; HT_HG-U133A	APC IFIT2 CAPN10 TAOK2 PKNOX2 SND1 RAB3GAP2 IL1RL1	9.27e-06	200	117	8	4014_DN
Drug	NSC381866	CLTCL1 CASP10 ATP6V0D1 TLR3 GPC5 ATP6V0D2 GOLGB1	2.74e-05	169	117	7	CID000002287
Drug	0317956-0000 [391210-11-0]; Down 200; 1uM; PC3; HT_HG-U133A	IPO8 TRIO TAOK2 GTF3C2 NF2 SENP7 MAP3K2	6.17e-05	192	117	7	4334_DN
Drug	(+,-)-Octopamine hydrochloride [770-05-8]; Down 200; 21uM; PC3; HT_HG-U133A	TRIO EPB41L5 TAOK2 EVI5 NF2 MAP3K2 DYRK2	6.37e-05	193	117	7	5050_DN
Drug	Trimethylcolchicinic acid [3482-37-9]; Down 200; 11.6uM; PC3; HT_HG-U133A	CLTCL1 SYNE1 APC TFAP4 CAPN10 PAFAH2 SENP7	6.37e-05	193	117	7	4202_DN
Drug	LY 294002; Up 200; 10uM; HL60; HT_HG-U133A	TRIO IFIT2 EVI5 NF2 PDE4DIP ELK3 IL1RL1	6.58e-05	194	117	7	2687_UP
Drug	Tadjakonine [11087-94-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	SYNE1 TFAP4 TBC1D4 NF2 SND1 DNAAF1 RASAL2	6.80e-05	195	117	7	2820_DN
Drug	Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A	TRIO TAOK2 PSME4 SND1 MAP3K2 PPP6R3 DYRK2	6.80e-05	195	117	7	3864_DN
Drug	Pempidine tartrate [546-48-5]; Up 200; 13uM; MCF7; HT_HG-U133A	KALRN DTNB TAOK2 PKNOX2 RAB3GAP2 IL1RL1 RASAL2	7.02e-05	196	117	7	6027_UP
Drug	Cefaclor [70356-03-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A	IPO8 APC EPB41L5 GTF3C5 TAOK2 PDE4DIP DNAAF1	7.02e-05	196	117	7	2843_DN
Drug	16, 16-dimethylprostaglandin E2 methyl acetate solution; Down 200; 10uM; MCF7; HT_HG-U133A	MON2 APC EPB41L5 EVI5 NF2 PAFAH2 PDE4DIP	7.25e-05	197	117	7	6597_DN
Drug	0198306-0000 [212631-61-3]; Down 200; 10uM; PC3; HT_HG-U133A	DYNC2H1 SYNE1 IFIT2 PSME4 NF2 PAFAH2 PDE4DIP	7.25e-05	197	117	7	7069_DN
Drug	Clemastine fumarate [14976-57-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A	ELOA VPS39 LRRC49 TFAP4 TAOK2 GTF3C2 PDE4DIP	7.49e-05	198	117	7	7443_DN
Drug	Carbetapentane citrate [23142-01-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A	SYNE1 TFAP4 TAOK2 RAB3GAP2 PAFAH2 PDE4DIP CARD14	7.49e-05	198	117	7	2623_UP
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Down 200; 13.2uM; PC3; HT_HG-U133A	APC CAPN10 EVI5 NF2 RAB3GAP2 PDE4DIP IL1RL1	7.49e-05	198	117	7	3990_DN
Drug	Doxycycline hydrochloride [10592-13-9]; Up 200; 8.4uM; HL60; HT_HG-U133A	TRIO KALRN NF2 PDE4DIP OSBPL7 IL1RL1 DNAAF1	7.49e-05	198	117	7	2737_UP
Drug	Meclozine dihydrochloride [1104-22-9]; Up 200; 8.6uM; HL60; HT_HG-U133A	DTNB CASP10 IFIT2 CREBBP NF2 RAB3GAP2 PDE4DIP	7.49e-05	198	117	7	2424_UP
Drug	Mephenesin [59-47-2]; Down 200; 22uM; PC3; HT_HG-U133A	APC GTF3C2 PAFAH2 MAP3K9 ELK3 RASAL2 MAP3K2	7.49e-05	198	117	7	3675_DN
Drug	Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; PC3; HT_HG-U133A	IPO8 APC TFAP4 EVI5 RAB3GAP2 IL1RL1 DYRK2	7.73e-05	199	117	7	3994_DN
Drug	Eucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; PC3; HT_HG-U133A	TRIO DYNC2H1 IFIT2 TAOK2 EVI5 PDE4DIP MAP3K2	7.73e-05	199	117	7	4316_DN
Drug	Propylthiouracil [51-52-5]; Down 200; 23.4uM; PC3; HT_HG-U133A	KANSL1L TRIO APC TFAP4 CAPN10 RAB3GAP2 PDE4DIP	7.97e-05	200	117	7	4076_DN
Drug	Moxisylyte hydrochoride [964-52-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	TRIO DYNC2H1 VPS39 TBC1D4 NINL IFT122 HTT	7.97e-05	200	117	7	7015_DN
Drug	N-phenylanthranilic acid; Down 200; 10uM; MCF7; HG-U133A	VPS39 APC CASP10 CUBN IFIT2 CAPN10 IFT122	7.97e-05	200	117	7	317_DN
Drug	Palmatine chloride [3486-67-7]; Down 200; 10.4uM; PC3; HT_HG-U133A	IPO8 TRIO SYNE1 APC GTF3C5 NF2 SND1	7.97e-05	200	117	7	6612_DN
Disease	Malignant neoplasm of breast	KALRN DYNC2H1 VPS39 SYNE1 SPATA18 BARD1 CUBN PRC1 NAA25 NF2 UNC45B NLRC5 ELK3 EP300 GOLGB1 RASAL2	4.86e-06	1074	116	16	C0006142
Disease	melanoma	CASP10 CUBN PPP6C NF2 MAP3K9 PLCB4 MAP2K2 EP300	6.47e-06	248	116	8	C0025202
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	1.53e-05	2	116	2	180849
Disease	Rubinstein-Taybi syndrome due to CREBBP mutations	CREBBP EP300	1.53e-05	2	116	2	cv:C4551859
Disease	Menke-Hennekam syndrome	CREBBP EP300	1.53e-05	2	116	2	cv:C5681632
Disease	Rubinstein-Taybi syndrome (implicated_via_orthology)	CREBBP EP300	1.53e-05	2	116	2	DOID:1933 (implicated_via_orthology)
Disease	Rubinstein-Taybi syndrome	CREBBP EP300	1.53e-05	2	116	2	cv:C0035934
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	1.53e-05	2	116	2	C4551859
Disease	Rubinstein-Taybi syndrome (is_implicated_in)	CREBBP EP300	1.53e-05	2	116	2	DOID:1933 (is_implicated_in)
Disease	Rubinstein-Taybi Syndrome	CREBBP EP300	1.53e-05	2	116	2	C0035934
Disease	Cerebellar Ataxia	SYNE1 SNX14	1.52e-04	5	116	2	C0007758
Disease	asthma, seasonal allergic rhinitis	CCDC91 RANBP6 IL1RL1	2.70e-04	32	116	3	EFO_0003956, MONDO_0004979
Disease	asthma, allergic disease	RANBP6 TLR10 EVI5 IL1RL1	2.71e-04	79	116	4	MONDO_0004979, MONDO_0005271
Disease	neuroimaging measurement	CCDC91 FBXL13 LRRC49 APC GINS1 TFAP4 TAOK2 SND1 RAB3GAP2 NINL ANKFN1 MYO16 HTT	3.01e-04	1069	116	13	EFO_0004346
Disease	lifestyle measurement, systolic blood pressure	KALRN CHFR	5.42e-04	9	116	2	EFO_0006335, EFO_0010724
Disease	Carcinoma, Transitional Cell	CREBBP CHD6 EP300	5.66e-04	41	116	3	C0007138
Disease	Human papillomavirus infectious disease (is_marker_for)	TLR3 IL1RL1	6.75e-04	10	116	2	DOID:11166 (is_marker_for)
Disease	anti-topoisomerase-I-antibody-positive systemic scleroderma	TLR10 IFT122	6.75e-04	10	116	2	EFO_0008537
Disease	Gastric cancer	APC CASP10	8.23e-04	11	116	2	cv:C0024623
Disease	Neoplasm of stomach	APC CASP10	8.23e-04	11	116	2	cv:C0038356
Disease	guanosine diphosphate measurement	TBC1D4 NINL	8.23e-04	11	116	2	EFO_0010494
Disease	GASTRIC CANCER	APC CASP10	8.23e-04	11	116	2	613659
Disease	lifestyle measurement, alcohol consumption measurement	RANBP6 NUP205 ELK3 UNC5D	1.12e-03	115	116	4	EFO_0007878, EFO_0010724
Disease	Mammary Carcinoma, Human	DYNC2H1 VPS39 SYNE1 SPATA18 BARD1 PRC1 ELK3 EP300	1.13e-03	525	116	8	C4704874
Disease	Mammary Neoplasms, Human	DYNC2H1 VPS39 SYNE1 SPATA18 BARD1 PRC1 ELK3 EP300	1.13e-03	525	116	8	C1257931
Disease	neuroblastoma	KANSL1L TRIO KALRN BARD1	1.16e-03	116	116	4	EFO_0000621
Disease	Mammary Neoplasms	DYNC2H1 VPS39 SYNE1 SPATA18 BARD1 PRC1 ELK3 EP300	1.16e-03	527	116	8	C1458155
Disease	Benign tumor of pancreas	APC EP300	1.16e-03	13	116	2	C0347284
Disease	Breast Carcinoma	DYNC2H1 VPS39 SYNE1 SPATA18 BARD1 PRC1 ELK3 EP300	1.32e-03	538	116	8	C0678222
Disease	alcohol dependence measurement	FAM114A1 PKNOX2 MYO16	1.34e-03	55	116	3	EFO_0007835
Disease	femoral neck bone geometry	CCDC91 PPP6R3	1.35e-03	14	116	2	EFO_0004511
Disease	sexual dimorphism measurement	CCDC91 DOCK3 USP49 SPATA18 APC MAP3K3 TAOK2 ABCE1 CDK5RAP1 NLRC5 DOT1L PPP6R3	1.39e-03	1106	116	12	EFO_0021796
Disease	Benign neoplasm of stomach	APC CASP10	2.00e-03	17	116	2	C0153943
Disease	Eye Abnormalities	APC IFT122	2.00e-03	17	116	2	C0015393
Disease	Neoplasm of uncertain or unknown behavior of stomach	APC CASP10	2.00e-03	17	116	2	C0496905
Disease	protein C measurement	FRMD6 MAP3K2	2.00e-03	17	116	2	EFO_0004633
Disease	Carcinoma in situ of stomach	APC CASP10	2.00e-03	17	116	2	C0154060
Disease	rhinitis	RANBP6 IL1RL1	2.00e-03	17	116	2	EFO_0008521
Disease	bipolar I disorder	SYNE1 CUBN CAPN10 MYO16	2.37e-03	141	116	4	EFO_0009963
Disease	Pancreatic carcinoma	APC EP300	2.51e-03	19	116	2	C0235974
Disease	leukemia (implicated_via_orthology)	PKNOX2 DOT1L	2.51e-03	19	116	2	DOID:1240 (implicated_via_orthology)
Disease	eosinophil percentage of leukocytes	DOCK3 KIF27 CCDC18 NAP1L4 RANBP6 NUP205 NLRC5 IL1RL1 MAP2K2	2.78e-03	746	116	9	EFO_0007991
Disease	urinary microalbumin measurement	MON2 CUBN	2.78e-03	20	116	2	EFO_0010967
Disease	Testicular Germ Cell Tumor	CENPE CDKL2 PKNOX2	3.01e-03	73	116	3	EFO_1000566
Disease	Stomach Carcinoma	APC CASP10	3.06e-03	21	116	2	C0699791
Disease	blood pressure	SYNE1 MYO16	3.36e-03	22	116	2	EFO_0004325
Disease	Non-Small Cell Lung Carcinoma	APC CHFR MAP2K2 DEUP1	3.40e-03	156	116	4	C0007131
Disease	idiopathic pulmonary fibrosis (is_marker_for)	IL1RL1 EP300	3.67e-03	23	116	2	DOID:0050156 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
NKLIVVVHACRNLIA	ESYT2	801	A0FGR8
QLVLLLHAHKCQRRE	EP300	341	Q09472
QLCSKLRNLLHDNEL	BARD1	106	Q99728
QQLVLLLHAHKCQRR	CREBBP	356	Q92793
RTCRQLLHLKDQCLI	CAPN10	206	Q9HC96
NLQAECRKHRLLLEE	ANKRD36	1761	A6QL64
QLLSHCQAQKEEIRR	DOT1L	531	Q8TEK3
LQLHRELLKIGECQN	DEUP1	291	Q05D60
IRNQIIRELQVLHEC	MAP2K2	111	P36507
NRQVICVTLKVLQHL	PACRG	161	Q96M98
VQHCLALLNLTLQKE	NUP205	846	Q92621
LRVQELIKLICNVQA	PARP2	236	Q9UGN5
KQLEDCLILQTLLHS	RAB3GAP2	891	Q9H2M9
RINALKQLQVRCAHI	NAP1L4	66	Q99733
DLECKIQQLTDIHRQ	KANSL1L	391	A0AUZ9
RQLISDHVDLVLCQK	MKKS	281	Q9NPJ1
VCANHIILCQEKRLQ	IFT122	441	Q9HBG6
CIEQHQLNKERELIE	MCU	191	Q8NE86
PNLEVLDCRHNLLKQ	LRRIQ4	421	A6NIV6
HADQLNDLCLQLQRK	MYO16	1136	Q9Y6X6
HLNGQKLLEQVNRIC	GPC5	331	P78333
NLNHCLELIEQVAKV	SPATA18	36	Q8TC71
CHKVVRDILLEQSLQ	KIAA2026	656	Q5HYC2
IQEHQELANECLLIL	KCNQ4	121	P56696
IVLCAIQNELELHKE	FSIP2	1301	Q5CZC0
DHLKLQCDRRLTLQQ	KIF27	1156	Q86VH2
LKDQIAELNHELRCL	EVI5	696	O60447
EICANIIREKLLEHL	ERAL1	346	O75616
QTHKRLEQCLQLRHL	KALRN	881	O60229
LEQCLQLRHLQAEVK	KALRN	886	O60229
NALECEIQLLKNLLH	MAP3K2	401	Q9Y2U5
EIQLLKNLLHERIVQ	MAP3K2	406	Q9Y2U5
RNKEELACALVHILQ	RASAL2	326	Q9UJF2
TKIENINHLCELRVL	LRRC49	191	Q8IUZ0
INHLCELRVLNLARN	LRRC49	196	Q8IUZ0
NHPDIRLKQLECVLQ	MON2	876	Q7Z3U7
TLRLQKCQLQVHDAE	NLRC5	846	Q86WI3
RVNKLILQLCIGNHD	NF2	291	P35240
KQLRHENLVNLLEVC	CDKL2	56	Q92772
CLHQIQKNKEDIIEL	CUBN	81	O60494
ESLNIIINVKILCHQ	FRMD6	26	Q96NE9
IINVKILCHQLLVQV	FRMD6	31	Q96NE9
ILCHQLLVQVCDLLR	FRMD6	36	Q96NE9
IQDALKNHRTVCELL	DYNC2H1	1761	Q8NCM8
CQQLDLTHLKERNVE	ABCE1	201	P61221
VERICKNHILNNLVE	CHFR	346	Q96EP1
QHDRKCIPLNIDLLN	EPB41L5	441	Q9HCM4
LKLQERVLNNVVIHL	HTT	901	P42858
LHCALIQNDAKVILI	IL1RL1	466	Q01638
KEVLLRRCQQLQEHL	CARD14	146	Q9BXL6
ERKQVHILQQNCIAL	CCDC150	251	Q8NCX0
HLRQQKELLICSGIL	DOCK3	866	Q8IZD9
TLHQQCIRVLKNNID	ELOA	576	Q14241
ALEICKEELVLHLNQ	CCDC18	731	Q5T9S5
KCEELLNAQHQRLLE	CCDC91	246	Q7Z6B0
QVLKCPQLHERLQLC	CHD6	1551	Q8TD26
VIINRLDNICHVVLK	CHD6	2096	Q8TD26
LKQRNLHNCVNIILL	ENPP3	356	O14638
LRFVQKRCNLHLVDI	DTNB	41	O60941
LKNILLRIQQIIYCH	FBXL13	71	Q8NEE6
LLQLLLDQKHEHLIC	ELK3	11	P41970
LECLRKAEELIQQEH	IFIT2	71	P09913
EDIQHLQECLRLCVL	DNAAF1	211	Q8NEP3
LLQHLNCTKEEVERL	CASP10	91	Q92851
LRQHCNRLNIEELLK	AHCTF1	896	Q8WYP5
QLLKHENVVNLIEIC	CDK9	71	P50750
SILQCLDALHKNRII	DYRK2	331	Q92630
LRIHLLELEKVNELC	PKNOX2	141	Q96KN3
KELLIKIQHLQQDCD	CENPE	2206	Q02224
ERELNIIIHQLCQEK	MAP3K9	481	P80192
CEIQLLKNLQHERIV	MAP3K3	411	Q99759
ARCIEQLHKVAELIL	FAM114A1	456	Q8IWE2
HQRVSECLRVLKILQ	PAFAH2	186	Q99487
LSECQGKLQELHRLL	OSBPL7	201	Q9BZF2
CLRIIDLVLQKHVIE	IPO8	636	O15397
EDIRELILKLHLQQQ	SENP7	1031	Q9BQF6
ERLQIDIQHLCLNKI	TRMT13	236	Q9NUP7
KLHPQQVLNRCIQEE	SLFN14	166	P0C7P3
QCELLKKLLINAHEQ	PLCB4	1046	Q15147
VLILCHNRIQQLDLK	TLR10	76	Q9BXR5
REQQKLQSVLEEIHC	SYNE1	3211	Q8NF91
SIVCLQKALNHLREI	PRC1	11	O43663
THELQSCLKQIIRNI	SETX	581	Q7Z333
LTLLITERQQKHCLA	SHISA4	66	Q96DD7
LLQRDVQIILESCHN	SND1	256	Q7KZF4
TQKDLECALLLRQHE	TAOK2	671	Q9UL54
VNICLQNLIHEKELS	SAPCD1	106	Q5SSQ6
FLDRQELTQLCLKLH	NINL	26	Q9Y2I6
ELTQLCLKLHLEQQL	NINL	31	Q9Y2I6
ILQKHCRIIKNVQVL	PHAF1	31	Q9BSU1
HDLDIIKRLLDQCIQ	RANBP6	176	O60518
IKRLLDQCIQDQEHP	RANBP6	181	O60518
KELLCRLQKLHLQHQ	CCDC136	416	Q96JN2
ILCHVKIRENNNISR	ANKFN1	636	Q8N957
LRENNCLQTLLQHLK	APC	656	P25054
QLNKLESLELCHLVL	CLTCL1	426	P53675
CHLVLQQGRKQLLEK	CLTCL1	436	P53675
QLIHERDNICKQIHL	CDK5RAP1	386	Q96SZ6
EILQRLCLHDQLSVQ	UNC45B	851	Q8IWX7
LICRRHQEIKNLICE	TRIM77	91	I1YAP6
KLEILDLQHNNLARL	TLR3	531	O15455
QECLLEEVAQQKHVL	RIPOR3	646	Q96MK2
LQCKLEQLFQEHRLV	SNX14	831	Q9Y5W7
HINNLKLICRAHQLV	PPP6C	226	O00743
QEFLCELLHKVQQEL	USP49	401	Q70CQ1
ICIRQLKGHEQILQV	UNC5D	806	Q6UXZ4
EQLVKILQRTLHLTC	PSME4	696	Q14997
LHRACINNQVEKLIL	SLF1	811	Q9BQI6
NELVILHLRQLCEAK	TBC1D4	511	O60343
KHLLQQCRLVERILT	PPP6R1	431	Q9UPN7
LQLLRQEHEERLQKI	UBL4B	111	Q8N7F7
QLCLDRLQLEAIHKV	GTF3C2	826	Q8WUA4
LKCLLNLQIQHIDAR	TASOR2	2371	Q5VWN6
CDLNVEELQKIIHRN	GTF3C5	411	Q9Y5Q8
ALELLHNCVQELKLL	TRAPPC10	331	P48553
KCEQLIRQGVLEHIL	GINS1	181	Q14691
NLLLKHLFQKCQLIE	PPP6R3	421	Q5H9R7
HLFQKCQLIERILEA	PPP6R3	426	Q5H9R7
SQILAVIRELKCLLH	ZYG11A	246	Q6WRX3
LLHQEKLEREQQQLR	TFAP4	206	Q01664
CVQLRHLQAEVKQVL	TRIO	906	O75962
RVQEERILHQQVKCI	VPS39	831	Q96JC1
LVQCETLEDLKIHLQ	ATP6V0D2	36	Q8N8Y2
LVQCETLEDLKLHLQ	ATP6V0D1	36	P61421
LLNHCAVLEKQVQEL	GOLGB1	3086	Q14789
VCKVVLHRLIQDSNQ	MYO5C	716	Q9NQX4
ADIRALQQHLCVVQL	NAA25	406	Q14CX7
QLSREKQQLLHLLEE	PDE4DIP	191	Q5VU43
SRLQHKLVLLQQQCE	PDE4DIP	1986	Q5VU43